Loading
eGFR ≥90 with kidney damage markers — most patients have no symptoms. Here's how to protect your kidneys now.
Evidence reviewed & updated: 2026-07 — based on KDIGO 2024, KDOQI, and published trial data.
Stage 1 kidney disease means your eGFR is normal (≥90 mL/min/1.73m²) but there are signs of kidney damage — usually protein (albumin) in the urine, blood in the urine, or structural abnormalities on imaging. Most people at stage 1 feel completely normal. The goal: stop progression with blood pressure control, SGLT2 inhibitors (if eligible), diabetes management, and lifestyle change.
CKD staging (KDIGO) uses two things: eGFR (how well the kidneys filter) and kidney damage markers. Stage 1 = eGFR ≥90 PLUS at least one marker of damage: albuminuria (UACR ≥30 mg/g), hematuria (persistent blood in urine), or structural abnormality (cysts, scarring, small kidneys on ultrasound).
Without damage markers, an eGFR of 90+ is simply normal aging-adjusted function — not CKD. That's why the diagnosis matters: it converts 'normal numbers' into an active monitoring plan.
Common causes at stage 1: diabetic kidney disease (early), hypertensive nephropathy (early), IgA nephropathy, and polycystic kidney disease. These can be silent for years — which is why urine testing is essential.
Some causes of stage 1 kidney disease are reversible or arrestable: acute insults (dehydration, nephrotoxins), early diabetic kidney disease (with SGLT2 inhibitors + glycemic control), and certain glomerulonephritides responding to treatment.
For most chronic causes, 'reversal' isn't the goal — STABILIZATION is. The evidence (RENAAL, DAPA-CKD, EMPA-KIDNEY trials) shows that aggressive early treatment dramatically slows or halts progression. Patients diagnosed and treated at stage 1-2 can live out normal lifespans without ever needing dialysis.
The key message: stage 1 is the golden window. This is where treatment has the highest leverage per rupee.
Medical: (1) blood pressure <130/80 mmHg (KDIGO target) with ACE inhibitor or ARB as first-line if albuminuric, (2) SGLT2 inhibitor (dapagliflozin/empagliflozin) if eGFR >20 — discussed for ALL albuminuric patients per KDIGO 2024, (3) diabetes control: HbA1c target ~7% with SGLT2i + GLP-1 prioritization, (4) annual UACR and eGFR monitoring.
Lifestyle: sodium <2g/day, protein intake 0.8-1.0 g/kg/day (not excess), smoking cessation, alcohol moderation, and daily physical activity (150 min/week).
Avoid: NSAIDs (ibuprofen, diclofenac — common in India as over-the-counter painkillers), unmonitored herbal supplements, and dehydration. Check creatinine 1-2 weeks after starting any new medication.
Advertisement
eGFR 60-89 with kidney damage — still mostly silent, but the protection plan tightens.
Learn moreKidney disease is silent — but these 10 warning signs deserve a urine and blood test today.
Learn moreDiabetes is the #1 cause of kidney failure in India — here's how to protect your kidneys with SGLT2 inhibitors, BP control, and smart monitoring.
Learn moreZuvFlo is ready to integrate with your facility to streamline operations, automate compliance, and deliver better patient care.
No credit card required • Setup in under 2 hours • Cancel anytime
Advertisement
This content is a general reference, not medical advice, a diagnosis, or a treatment plan. Do not change your diet, fluids, medicines, or dialysis plan without your nephrologist or renal dietitian. Individual recommendations depend on your labs, medications, conditions, and care plan.